within Pharmacolibrary.Drugs.ATC.M;

model M01CB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.043333333333333335,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Sodium aurothiomalate is a gold-containing compound formerly used primarily in the treatment of rheumatoid arthritis as a disease-modifying antirheumatic drug (DMARD). It is administered parenterally, usually by intramuscular injection. Its use has largely declined due to safety concerns and the availability of more effective agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with rheumatoid arthritis. Values are typically reported in clinical studies from patients treated with intramuscular sodium aurothiomalate.</p><h4>References</h4><ol><li>P N Bennett, S J Humphries, J P Osborne, A K Clarke, A Taylor,Use of sodium aurothiomalate during lactation.,British journal of clinical pharmacology,1990<a href='https://pubmed.ncbi.nlm.nih.gov/2116162/'>https://pubmed.ncbi.nlm.nih.gov/2116162/</a></li><li>B Bannwarth, L Labat, Y Moride, T Schaeverbeke,Methotrexate in rheumatoid arthritis. An update.,Drugs,1994<a href='https://pubmed.ncbi.nlm.nih.gov/7510620/'>https://pubmed.ncbi.nlm.nih.gov/7510620/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01CB01;
